Healthcare>Healthcare>Pharmaceuticals & Biotechnology>Pharmaceuticals
₹1,472.80
8.70 (0.59%)
High VOLATILITY
As on 12 Jun 2026
Price History
Market Cap
The total value of all a company's shares of stock. It's a quick way to gauge a company's size and value.
₹85.54K Cr
MID CAP
P/E Ratio
Price-to-Earnings ratio. It shows how much you pay for ₹1 of the company's earnings. A lower P/E might mean it's undervalued, but it varies by industry.
24.1
Industry
The specific business sector the company operates in. Useful for comparing with similar companies.
Pharmaceuticals
52-Week Range
The highest and lowest price at which the stock has traded in the last year (52 weeks). It helps show how volatile the stock is and where it is currently priced relative to its recent history.
52W Low₹1,016.1+44.9%
52W High₹1,550-5.0%
Current Price
₹1,472.80
Circuit Limits (20%)
The maximum allowed price movement (up or down) in a single trading day to prevent excessive volatility. If the stock hits these limits, trading may be temporarily halted.
Lower Circuit₹1,178.24
Upper Circuit₹1,767.36
Reference Price
₹1,472.80
Investment Checklist
Inverse Head and Shoulders on 1W (BREAKOUT CONFIRMED) — target ₹1377.9
Triple Bottom on 1D (BREAKOUT CONFIRMED) — target ₹1324.1
Trend: Price above all key MAs — strong uptrend | Bullish MA stack (20>50>200)
Volume divergence: Bearish (price up, volume down)
SuperTrend(10,3): Price below SuperTrend (Industry Standard (Swing/Medium-Term))
Technical Analysis
Technical Analysis
Analysis from 2026-06-12
Confidence
76%
Trend
BULLISH
BULLISH
Price above all key MAs — strong uptrend | Bullish MA stack (20>50>200)
EMA20
1457.38
EMA50
1423.49
EMA200
1276.02
Price Action
MIXED
NEUTRAL
Higher Highs5
Higher Lows5
Lower Highs4
Lower Lows4
Support & Resistance Levels
Resistance (Above)
₹1496.50
₹1550.00
Support (Below)
₹1459.50
₹1411.00
₹1363.45
₹1324.90
₹1267.27
Volume Analysis
TrendDECREASING
Change-35.20%
Unusual VolumeNo
Divergence Detected
Bearish (price up, volume down)
Stop Loss Levels
Fixed Risk
1% Risk₹1458.07
3% Risk₹1428.62
5% Risk₹1399.16
7% Risk (Custom)
₹1369.70Technical Levels
1x ATR (Volatility)₹1438.30
2x ATR (Swing)₹1403.80
3x ATR (Trend)₹1369.30
Immediate Support₹1459.50
Moving Averages
EMA 9 (Short-term)₹1458.87
EMA 20 (Medium-term)₹1457.38
EMA 50 (Trend)₹1423.49
EMA 200 (Long-term)₹1276.02
Financials
Financial Analysis
| Metric | Dec '24 | Mar '25 | Jun '25 | Dec '25 |
|---|---|---|---|---|
| Revenue | ₹7,893.2 Cr | ₹8,381.1 Cr | ₹7,791.8 Cr | ₹8,604.5 Cr |
| Net Profit | ₹845.8 Cr | ₹903.5 Cr | ₹824.8 Cr | ₹910.3 Cr |
| EPS | ₹14.56 | — | ₹14.20 | ₹15.67 |
| Operating Profit | ₹1,736.9 Cr | ₹1,819.5 Cr | ₹1,710.3 Cr | ₹1,896 Cr |
Peer Comparison
PharmaceuticalsPeer Comparison
| Symbol | Name | Price | Change |
|---|---|---|---|
| SUNPHARMA | Sun Pharmaceutical Industries Limited | ₹1,807.70 | +0.75% |
| DIVISLAB | Divi's Laboratories Limited | ₹6,638.00 | -0.26% |
| TORNTPHARM | Torrent Pharmaceuticals Limited | ₹4,571.20 | -0.02% |
| CIPLA | Cipla Limited | ₹1,389.40 | +0.44% |
| ZYDUSLIFE | Zydus Lifesciences Limited | ₹1,104.70 | -0.11% |
| DRREDDY | Dr. Reddy's Laboratories Limited | ₹1,275.40 | -0.05% |
| LUPIN | Lupin Limited | ₹2,293.30 | +0.88% |
| MANKIND | Mankind Pharma Limited | ₹2,381.10 | +0.35% |
| LAURUSLABS | Laurus Labs Limited | ₹1,394.30 | +0.25% |
| BIOCON | Biocon Limited | ₹419.00 | +0.73% |
Corporate Information
Large Deals
View AllBulk, Block and Short deals reported for this stock.
Loading Deals...
Corporate Actions
Recent actions
| Ex Date | Purpose | Type |
|---|---|---|
| 17 Apr 2026 | Buy Back | BUYBACK |
| 08 Aug 2025 | Interim Dividend - Rs 4 Per Share | INTERIM_DIVIDEND |
| 26 Aug 2024 | Annual General Meeting | AGM |
| 30 Jul 2024 | Buy Back | BUYBACK |
| 20 Feb 2024 | Interim Dividend - Rs 1.50 Per Share | INTERIM_DIVIDEND |
Announcements
Latest updates
Board Meetings
Upcoming and past meetings
Corporate Events
Upcoming results & meetings
No upcoming events found
We couldn't find any scheduled corporate actions for this symbol at the moment.
Latest News
News for AUROPHARMA
View AllNEWS
positive
Business Standard - Markets 3h ago
Aurobindo Pharma's Eugia Unit-III receives OAI classification from USFDA
Aurobindo Pharma has announced that the United States Food and Drug Administration (USFDA) has classified its Eugia Unit-III manufacturing facility as "Official Action Indicated" (OAI) following an inspection conducted earlier this year.
AUROPHARMAHealthcare
positive
CNBC TV18 - Markets 20h ago
Aurobindo Pharma unit in Telangana classified "OAI" by US FDA after inspection
Shares of Aurobindo Pharma Ltd ended at ₹1,469.30, up by ₹5.20, or 0.36%, on the BSE.
AUROPHARMABSEFinancial ServicesHealthcare
NEWS
positive
Business Standard - Markets 8d ago
Aurobindo Pharma gains after receiving USFDA approval for Tofacitinib tablets
Aurobindo Pharma rose 1.80% to Rs 1,489.95 after the company announced that it has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Tofacitinib Tablets in 5 mg and 10 mg strengths.
AUROPHARMAHealthcare